Clinical Trial Update: 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for 18F-DCFPyL PET/CT in high-risk and recurrent prostate cancer, with status currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Neoplasms, Prostatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING